Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This protocol is for the treatment of toxic plasma methotrexate concentrations (>1 micromole
per liter) in patients with delayed methotrexate clearance due to impaired renal function